NZ602515A - Proteins that bind pi16 and uses thereof - Google Patents

Proteins that bind pi16 and uses thereof

Info

Publication number
NZ602515A
NZ602515A NZ602515A NZ60251511A NZ602515A NZ 602515 A NZ602515 A NZ 602515A NZ 602515 A NZ602515 A NZ 602515A NZ 60251511 A NZ60251511 A NZ 60251511A NZ 602515 A NZ602515 A NZ 602515A
Authority
NZ
New Zealand
Prior art keywords
protein
disclosed
binding
bind
proteins
Prior art date
Application number
NZ602515A
Other languages
English (en)
Inventor
Nicola Ga-Ling Eastaff-Leung
Heddy Zola
Doreen Krumbiegel
Ian Cameron Nicholson
Simon Barry
Original Assignee
Transbio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transbio Ltd filed Critical Transbio Ltd
Priority to NZ701408A priority Critical patent/NZ701408A/en
Publication of NZ602515A publication Critical patent/NZ602515A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
NZ602515A 2010-04-16 2011-04-18 Proteins that bind pi16 and uses thereof NZ602515A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ701408A NZ701408A (en) 2010-04-16 2011-04-18 Proteins that bind pi16 and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32509310P 2010-04-16 2010-04-16
US201061426019P 2010-12-22 2010-12-22
PCT/AU2011/000498 WO2011127543A1 (fr) 2010-04-16 2011-04-18 Protéines qui se lient à pi16 et leurs utilisations

Publications (1)

Publication Number Publication Date
NZ602515A true NZ602515A (en) 2015-06-26

Family

ID=44798187

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ602515A NZ602515A (en) 2010-04-16 2011-04-18 Proteins that bind pi16 and uses thereof
NZ701408A NZ701408A (en) 2010-04-16 2011-04-18 Proteins that bind pi16 and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ701408A NZ701408A (en) 2010-04-16 2011-04-18 Proteins that bind pi16 and uses thereof

Country Status (7)

Country Link
US (1) US9605079B2 (fr)
EP (1) EP2558500A4 (fr)
JP (2) JP6046032B2 (fr)
AU (1) AU2011241483B2 (fr)
CA (1) CA2795078A1 (fr)
NZ (2) NZ602515A (fr)
WO (1) WO2011127543A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ602515A (en) * 2010-04-16 2015-06-26 Transbio Ltd Proteins that bind pi16 and uses thereof
CN107002065B (zh) * 2014-08-22 2019-04-26 日东纺绩株式会社 对TRACP-5b（酒石酸抵抗性酸性磷酸酶5b）具有特异性的蛋白定量法
EP3538141A4 (fr) * 2016-11-10 2020-07-15 Merck Sharp & Dohme Corp. Ligand ilt3
EP3450981A1 (fr) * 2017-08-28 2019-03-06 Trizell GmbH Btnl8 en tant que marqueur de tregs
JP7271539B2 (ja) * 2017-11-14 2023-05-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル リンホトキシンアルファ遺伝子について遺伝的に改変された調節性ｔ細胞及びその使用
EP3710479A2 (fr) 2017-11-17 2020-09-23 Merck Sharp & Dohme Corp. Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations
CN108017711B (zh) * 2017-11-28 2020-05-26 孙伟 一种抗钙化短肽及其应用
CN113024642B (zh) * 2021-03-08 2022-09-20 珠海丽禾医疗诊断产品有限公司 一种基于肺炎支原体的蛋白质及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856130A (en) 1996-12-26 1999-01-05 Incyte Pharmaceuticals, Inc. Human pathogenesis-related protein
US7534580B2 (en) * 2002-05-01 2009-05-19 Ambrilia Biopharma Inc. PSP94 diagnostic reagents and assays
CA2391438A1 (fr) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Reactifs et methodes diagnostiques a base de psp94
EP1913387B1 (fr) * 2005-08-02 2016-01-20 Centenary Institute of Cancer Medicine & Cell Biology Procédé destiné à identifier des lymphocytes t régulateurs
AU2007221234A1 (en) 2006-02-24 2007-09-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Extracellular matrix/metastasis modifer genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor
CA2655392A1 (fr) * 2006-05-31 2007-12-06 The Regents Of The University Of California Expression de cd127 inversement proportionnelle a foxp3 et fonction suppressive des tregs cd4+
WO2008110356A2 (fr) 2007-03-12 2008-09-18 Robert Frost Protéines secrétées à partir du cœur et utilisations de celles-ci
JP5616782B2 (ja) 2008-03-14 2014-10-29 株式会社メディネット 免疫増強機能を有する抗体
WO2009143624A1 (fr) 2008-05-30 2009-12-03 The University Of British Columbia Procédés de diagnostic d'un rejet d'une allogreffe de rein à l'aide d'un profilage d'expression génomique ou protéomique
AU2010225456B2 (en) * 2009-03-18 2016-03-17 Carina Biotech Pty Ltd Biomarkers and uses thereof
NZ602515A (en) * 2010-04-16 2015-06-26 Transbio Ltd Proteins that bind pi16 and uses thereof

Also Published As

Publication number Publication date
AU2011241483A1 (en) 2012-10-11
US20130171153A1 (en) 2013-07-04
NZ701408A (en) 2016-01-29
CA2795078A1 (fr) 2011-10-20
WO2011127543A1 (fr) 2011-10-20
EP2558500A1 (fr) 2013-02-20
JP2013527836A (ja) 2013-07-04
AU2011241483B2 (en) 2015-06-25
EP2558500A4 (fr) 2014-04-23
JP2016222708A (ja) 2016-12-28
US9605079B2 (en) 2017-03-28
JP6046032B2 (ja) 2016-12-14

Similar Documents

Publication Publication Date Title
NZ602515A (en) Proteins that bind pi16 and uses thereof
MX2020001873A (es) Agentes de union.
NZ599875A (en) Human il-23 antigen binding proteins
MY166776A (en) Humanised anti-ctla4 antibodies
WO2007133822A8 (fr) Anticorps anti-gitr destinés au traitement du cancer
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
EP3539988A3 (fr) Anticorps monoclonaux contre her2
NZ601271A (en) Cd127 binding proteins
MY165273A (en) Anti-cd48 antibodies and uses thereof
AU2010220421A8 (en) Antibodies against a proliferating inducing ligand (APRIL)
WO2013048883A3 (fr) Anticorps anti-erbb3 et leurs utilisations
NZ612272A (en) Anti-cd38 antibodies
AU2010217100A8 (en) Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
WO2013013025A3 (fr) Anticorps anti-cxcr4 et leurs procédés d'utilisation
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MX2019000046A (es) Anticuerpos anti-il-23.
TN2014000120A1 (en) Cd27l antigen binding proteins
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
CA2821268C (fr) Anticorps monoclonal humain ayant une specificite pour la proteine e du virus de la dengue de serotype 1 et utilisations de celui-ci
MX2013007067A (es) Anticuerpos anti-il-18 y sus usos.
TN2010000616A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
NZ595863A (en) Antibodies to egfl7 and methods for their use
WO2012006341A3 (fr) Anticorps anti-ron

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: MEDVET SCIENCE PTY LTD, AU

Effective date: 20150917

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 APR 2018 BY FB RICE

Effective date: 20151009

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2019 BY FB RICE PTY LTD

Effective date: 20180319

ASS Change of ownership

Owner name: CARINA BIOTECH PTY LTD, AU

Effective date: 20180329

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2020 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20190411

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2021 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20200121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2022 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20210405

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2023 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20220407

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2024 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20230411

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2025 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20240201